TIL

Instil Bio, Inc. (TIL) - Form 10-Q Summary

Business Context and Reporting Period

Instil Bio, Inc. is a biotechnology company focused on identifying and advancing innovative therapeutic opportunities. This report covers the quarterly period ended June 30, 2026. The Company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. In January 2026, the Company's subsidiary, Axion Bio, Inc., discontinued development of its former lead product candidate, AXN-2510.

Key Financial Metrics

Note: The Company has no product revenue. "Other rental income" of $2.2 million (quarterly) and $4.5 million (six-month) is derived from leasing the Tarzana facility to AstraZeneca and is not considered core operating revenue.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased significantly to $4.3 million for the quarter (from $21.4 million in Q2 2025) and $8.5 million for the six months (from $49.6 million in the prior year period). This improvement is primarily due to the discontinuation of the AXN-2510 program and the absence of a $10 million in-process research and development (IPR&D) charge recorded in the prior year.
• Operating Expenses: Total operating expenses dropped to $5.6 million for the quarter (from $23.4 million) and $12.6 million for the six months (from $54.0 million). Research and development expenses fell to $0.3 million (quarterly) and $0.9 million (six-month) compared to $6.7 million and $12.1 million, respectively, in the prior year periods.
• Restructuring and Impairment: Charges decreased to $0.2 million (quarterly) and $1.2 million (six-month) compared to $0.5 million and $16.6 million in the prior year. The 2026 charges relate to the reclassification of the Tarzana facility from "held for sale" to "held and used" and employee terminations, whereas 2025 charges included significant impairment and estimated costs to sell the facility.
• Gain on Contract Termination: The Company recognized a $1.6 million gain in the first half of 2026 from the termination of the collaboration agreement with ImmuneOnco regarding AXN-2510.

Outlook, Risks, and Management Commentary

• Going Concern: Management has identified substantial doubt about the Company's ability to continue as a going concern. The 2024 Loan of $85.6 million matures in January 2027, which exceeds the Company's current cash, cash equivalents, and marketable securities ($69.9 million). Management plans to exercise a contractual option to extend the loan maturity to January 2028, which they believe alleviates the substantial doubt.
• Strategic Shift: Following the discontinuation of AXN-2510, the Company is actively seeking to in-license or acquire additional novel therapeutic candidates.
• Tarzana Facility: In May 2026, the Company decided to discontinue the plan to sell the Tarzana facility. The asset was reclassified from "held for sale" to "held and used," resulting in a net remeasurement loss of $0.2 million. The facility remains leased to AstraZeneca, providing steady rental income.
• Liquidity Strategy: The Company expects existing liquidity to fund operations beyond 2027. Future funding may be sought through equity or debt instruments, refinancing the 2024 Loan, or selling the Tarzana facility, though there is no assurance such financing will be available on favorable terms.
• Risk Factors: Risks include the inability to secure additional financing, potential additional impairment charges related to the Tarzana facility, and the uncertainty of future product development.

Investor Verification Checklist

• Debt Maturity & Extension: Verify the conditions required to exercise the one-year extension option on the $85.6 million 2024 Loan due in January 2027.
• Liquidity Runway: Confirm the Company's burn rate and whether current cash and marketable securities ($69.9 million) are sufficient to cover operating expenses and interest payments until the loan extension or refinancing is secured.
• Tarzana Facility Valuation: Review the fair value assessment of the Tarzana facility ($111.8 million carrying value) and the potential for future impairment if the asset cannot be sold or refinanced.
• Pipeline Status: Assess the progress of the Company's efforts to in-license or acquire new therapeutic candidates to replace the discontinued AXN-2510 program.
• Rental Income Stability: Monitor the lease agreement with AstraZeneca for the Tarzana facility, which provides the majority of the Company's non-operating income.